After reviewing comments from over 250 stakeholders, meeting with various interest groups and holding regular staff meetings, the U.S. Senate [...] …
Articles by : Ted Slafsky, Publisher & CEO
As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four hospital associations are asking a federal judge in Louisiana to throw out a suit filed by the drug industry [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
When I thought about launching 340B Report, the first person I reached out to was Tom Mirga. Tom and I [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Veteran 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
In what legal experts describe as a landmark decision, the U.S. District Court for the District of South Carolina ruled [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
According to our history lessons, George Washington told Thomas Jefferson that the Senate was created to serve as a saucer [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After a recent lull in the ongoing battle over whether drug manufacturers can continue to place restrictions on access to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Certain flexibilities to the 340B program allowed under the COVID-19 public health emergency will expire May 11 alongside the PHE, the U.S. Health Resources and Services Administration announced Monday.
The update, which HRSA posted prominently on the Office of Pharmacy
…
With just weeks to go in its legislative session, Missouri lawmakers are making progress on two different 340B anti-discrimination bills. Last week, a key Senate committee approved SB 26, comprehensive legislation with two key priorities: prohibiting drug manufacturers from placing
…